Retrospective Study of Gemcitabine Based Chemotherapy for Unresectable or Recurrent Esophagus Squamous Cell Carcinoma Refractory to First Line Chemotherapy |
Wang, Mei
(Oncology Department, Changhai hospital)
Gu, Jun (Gastroenterology Department, No 123 Hospital) Wang, Hai-Xing (Oncology Department, Changhai hospital) Wu, Mei-Hong (Oncology Department, Changhai hospital) Li, Yong-Mei (Oncology Department, Changhai hospital) Wang, Ya-Jie (Oncology Department, Changhai hospital) |
1 | Cuningham D, Starling N, Rao S (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med, 358, 36-46. DOI ScienceOn |
2 | Enzinger PC, Ryan DP, Clark JW (2009). Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol, 20, 475-80. |
3 | Grunberger B, Raderer M, Schmidinger M (2007). Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res, 27, 2705-14. |
4 | Hou YT, Qiao ZF, Song CY, Meng GH, Cheng HX (2007). Trends in incidence of esophageal and gastric cardia cancer in high-risk area in China. European Journal of Cancer prevention, 17, 71-6 |
5 | Hirata S, Yatsuyanagi E, Yamazaki H, et al (2000). Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone. Gan To Kagaku Ryoho, 27, 221-6. |
6 | Huang J, Fan QX, Chen L, et al (2011). Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial. Chin Med J, 124, 119-21. |
7 | Jin J, Xu X, Wang F (2009). Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatinpretreated refractory metastatic/recurrent esophageal squamous carcinoma. J Thorad Oncol, 4, 1017-21. DOI |
8 | Kaya AO, Buyukberber S, Ozkan M, Anatolian Society of Medical Oncology (ASMO) (2012). Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 13, 463-7. DOI |
9 | Nakajima Y, Suzuki T, Haruki S (2008). A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology, 55, 1631-5. |
10 | Shim HJ, Cho SH, Hwang JE (2010). Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin oretreated esophageal cancer. Am J Clin Oncol, 33, 624-9. DOI |
11 | Thallinger C, Raderer M, Hejna M (2011). Esophageal Cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol, 29, 4709-4. DOI |
12 | Yamazaki K, Hiraonaka S, Boku N (2008). A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refracrory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol, 13, 150-5. DOI |
13 | Yao CY, Huang XE, Tang JH, Xu HX (2010). Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pac J Cancer Prev, 11, 553-5. |
14 | Cao W, Xu C, Lou G, et al (2009). A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol, 39, 582. DOI |
15 | Brutnwss B, Gibson M, Egleston B (2009). Phase II trial of docetaxel-irinotecan combination in advanced esphageal cancer. Ann Oncol, 20, 1242-8. DOI ScienceOn |
![]() |